Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 660, Issue 1-2, 2009, Pages 1-11

  Carvalho, Marcelo ^a,e   Pino, Maria A ^b   Karchin, Rachel ^c   Beddor, Jennifer ^d   Godinho Netto, Martha ^e   Mesquita, Rafael D ^e   Rodarte, Renato S ^e,f   Vaz, Danielle C ^e   Monteiro, Viviane A ^e   Manoukian, Siranoush ^g   Colombo, Mara ^g   Ripamonti, Carla B ^g   Rosenquist, Richard ^h   Suthers, Graeme ⁱ   Borg, Ake ^j   Radice, Paolo ^g,k   Grist, Scott A ^l   Monteiro, Alvaro N A ^a   Billack, Blase ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Johns Hopkins University   (United States)

^e INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

^f FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^j LUND UNIVERSITY   (Sweden)

^k FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^l FLINDERS UNIVERSITY   (Australia)

more..

Author keywords

BRCA1; BRCT domain; Breast cancer; Functional analysis; Unclassified variants

Indexed keywords

BRCA1 PROTEIN; MESSENGER RNA;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER SUSCEPTIBILITY; COMPUTER MODEL; CONTROLLED STUDY; EXON; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE INACTIVATION; GENE INSERTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN FRAME DELETION; K1487R GENE; M16521 GENE; MISSENSE MUTATION; MUTATOR GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; Q1826H GENE; RELIABILITY; RISK ASSESSMENT; S1613C GENE; V1833M GENE;

BLOTTING, WESTERN; BRCA1 PROTEIN; CELL LINE; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; EXONS; FEMALE; FRAMESHIFT MUTATION; HUMANS; MALE; MODELS, GENETIC; MODELS, MOLECULAR; MUTATION, MISSENSE; PEDIGREE; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION; TRANSFECTION;

EID: 58249090764     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2008.09.017     Document Type: Article

References (57)

1. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., and Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
2. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
3. Begg C.B., Haile R.W., Borg A., Malone K.E., Concannon P., Thomas D.C., Langholz B., Bernstein L., Olsen J.H., Lynch C.F., Nton-Culver H., Capanu M., Liang X., Hummer A.J., Sima C., and Bernstein J.L. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299 (2008) 194-201
4. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M.D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T.R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B.A., Gayther S.A., and Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62 (1998) 676-689
5. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Fan I., Tang J., Li S., Zhang S., Shaw P.A., and Narod S.A. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 98 (2006) 1694-1706
6. Levy-Lahad E., and Plon S.E. Cancer, a risky business-assessing breast cancer risk. Science 302 (2003) 574-575
7. Narod S.A., and Offit K. Prevention and management of hereditary breast cancer. J. Clin. Oncol. 23 (2005) 1656-1663
8. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4 (2004) 665-676
9. Goldgar D.E., Easton D.F., Deffenbaugh A.M., Monteiro A.N., Tavtigian S.V., and Couch F.J. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet. 75 (2004) 535-544
10. Szabo C.I., Worley T., and Monteiro A.N. Understanding Germ-Line Mutations in BRCA1. Cancer Biol. Ther. 3 (2004) 515-520
11. Easton D.F., Deffenbaugh A.M., Pruss D., Frye C., Wenstrup R.J., len-Brady K., Tavtigian S.V., Monteiro A.N., Iversen E.S., Couch F.J., and Goldgar D.E. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet. 81 (2007) 873-883
12. Carvalho M.A., Couch F.J., and Monteiro A.N. Functional assays for BRCA1 and BRCA2. Int. J. Biochem. Cell Biol. 39 (2007) 298-310
13. Domchek S., and Weber B.L. Genetic variants of uncertain significance: flies in the ointment. J. Clin. Oncol. 26 (2008) 16-17
14. Carvalho M.A., Marsillac S.M., Karchin R., Manoukian S., Grist S., Swaby R.F., Urmenyi T.P., Rondinelli E., Silva R., Gayol L., Baumbach L., Sutphen R., Pickard-Brzosowicz J.L., Nathanson K.L., Sali A., Goldgar D., Couch F.J., Radice P., and Monteiro A.N.A. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 67 (2007) 1494-1501
15. Phelan C.M., Dapic V., Tice B., Favis R., Kwan E., Barany F., Manoukian S., Radice P., van der Luijt R.B., van Nesselrooij B.P., Chenevix-Trench G., Caldes T., De La H.M., Lindquist S., Tavtigian S.V., Goldgar D., Borg A., Narod S.A., and Monteiro A.N. Classification of BRCA1 missense variants of unknown clinical significance. J. Med. Genet. 42 (2005) 138-146
16. Vallon-Christersson J., Cayanan C., Haraldsson K., Loman N., Bergthorsson J.T., Brondum-Nielsen K., Gerdes A.M., Moller P., Kristoffersson U., Olsson H., Borg A., and Monteiro A.N. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum. Mol. Genet. 10 (2001) 353-360
17. Mirkovic N., Marti-Renom M.A., Weber B.L., Sali A., and Monteiro A.N. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res. 64 (2004) 3790-3797
18. Karchin R., Monteiro A.N., Tavtigian S.V., Carvalho M.A., and Sali A. Functional Impact of Missense Variants in BRCA1 Predicted by Supervised Learning. PLoS Comput. Biol. 3 (2007) e26
19. Williams R.S., and Glover J.N. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J. Biol. Chem. 278 (2003) 2630-2635
20. Johnson D.H. PCR: A Practical Approach (2003), IRL Press, Oxford
21. Golemis E.A., Gyuris J., and Brent R. Two-hybrid system/interaction traps. In: Ausubel F.M., Brent R., Kingston R., Moore D., Seidman J., Smith J.A., and Struhl K. (Eds). Current Protocols in Molecular Biology (1994), John Wiley & Sons, New York 13 pp. 14, 1-13, 14, 17
22. Estojak J., Brent R., and Golemis E.A. Correlation of two-hybrid affinity data with in vitro measurements. Mol. Cell Biol. 15 (1995) 5820-5829
23. Brent R., and Ptashne M. A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor. Cell 43 (1985) 729-736
24. Hayes F., Cayanan C., Barilla D., and Monteiro A.N. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res. 60 (2000) 2411-2418
25. Karchin R., Diekhans M., Kelly L., Thomas D.J., Pieper U., Eswar N., Haussler D., and Sali A. LS-SNP: large-scale annotation of coding non-synonymous SNPs based on multiple information sources. Bioinformatics 21 (2005) 2814-2820
26. Karchin R., Kelly L., and Sali A. Improving functional annotation of non-synonomous SNPs with information theory. Pac. Symp. Biocomput. (2005) 397-408
27. Karchin R., Agarwal M., Sali A., Couch F., and Beattie M. Classifying variants of undetermined significance in BRCA2 with protein likelihood ratios. Cancer Inform. 6 (2008) 9-12
28. Karplus K., Katzman S., Shackleford G., Koeva M., Draper J., Barnes B., Soriano M., and Hughey R. SAM-T04: what is new in protein-structure prediction for CASP6. Proteins 61 Suppl. 7 (2005) 135-142
29. Monteiro A.N. BRCA1: exploring the links to transcription. Trends Biochem. Sci. 25 (2000) 469-474
30. Glover J.N., Williams R.S., and Lee M.S. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem. Sci. 29 (2004) 579-585
31. Williams R.S., Chasman D.I., Hau D.D., Hui B., Lau A.Y., and Glover J.N. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. J. Biol. Chem. 278 (2003) 53007-53016
32. M. Tischkowitz, N. Hamel, M.A. Carvalho, G. Birrane, A. Soni, E.H. van Beers, S.A. Joose, N. Wong, D. Novak, L.A. Quenneville, S. Grist, kConFab, P.M. Nederlof, D.E. Goldgar, S.V. Tavtigian, A.N. Monteiro, J.A. Ladias, W.D. Foulkes, Pathogenicity of a BRCA1 missense variant is determined by the disruption of the phosphopeptide binding pocket - a multi-modal approach, Eur. J. Hum. Genet. 16 (2008) 820-832.
33. Williams R.S., Lee M.S., Hau D.D., and Glover J.N. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat. Struct. Mol. Biol. 11 (2004) 519-525
34. Varma A.K., Brown R.S., Birrane G., and Ladias J.A. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. Biochemistry 44 (2005) 10941-10946
35. Judkins T., Hendrickson B.C., Deffenbaugh A.M., Eliason K., Leclair B., Norton M.J., Ward B.E., Pruss D., and Scholl T. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res. 65 (2005) 10096-10103
36. Tavtigian S.V., Deffenbaugh A.M., Yin L., Judkins T., Scholl T., Samollow P.B., de S.D., Zharkikh A., and Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J. Med. Genet. 43 (2006) 295-305
37. Friedman L.S., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., and King M.C. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 8 (1994) 399-404
38. Szabo C.I., and King M.C. Inherited breast and ovarian cancer. Hum. Mol. Genet. 4 Spec No. (1995) 1811-1817
39. Lovelock P.K., Spurdle A.B., Mok M.T., Farrugia D.J., Lakhani S.R., Healey S., Arnold S., Buchanan D., Investigators K., Couch F.J., Henderson B.R., Goldgar D.E., Tavtigian S.V., Chenevix-Trench G., and Brown M.A. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?. Breast Cancer Res. 9 (2007) R82
40. Ng P.C., and Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 11 (2001) 863-874
41. Ramensky V., Bork P., and Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30 (2002) 3894-3900
42. Bao L., Zhou M., and Cui Y. nsSNPAnalyzer: identifying disease-associated nonsynonymous single nucleotide polymorphisms. Nucleic Acids Res. 33 (2005) W480-W482
43. Ferrer-Costa C., Gelpi J.L., Zamakola L., Parraga I., l.C.de X., and Orozco M. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21 (2005) 3176-3178
44. Mi H., Guo N., Kejariwal A., and Thomas P.D. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 35 (2007) D247-D252
45. Monteiro A.N., August A., and Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13595-13599
46. Chapman M.S., and Verma I.M. Transcriptional activation by BRCA1. Nature 382 (1996) 678-679
47. Joo W.S., Jeffrey P.D., Cantor S.B., Finnin M.S., Livingston D.M., and Pavletich N.P. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev. 16 (2002) 583-593
48. Williams R.S., Green R., and Glover J.N. Crystal structure of the BRCT repeat region from the breast cancer- associated protein BRCA1. Nat. Struct. Biol. 8 (2001) 838-842
49. Monteiro A.N., August A., and Hanafusa H. Common BRCA1 variants and transcriptional activation. Am. J. Hum. Genet. 61 (1997) 761-762
50. Deffenbaugh A.M., Frank T.S., Hoffman M., Cannon-Albright L., and Neuhausen S.L. Characterization of common BRCA1 and BRCA2 variants. Genet. Test. 6 (2002) 119-121
51. Humphrey J.S., Salim A., Erdos M.R., Collins F.S., Brody L.C., and Klausner R.D. Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5820-5825
52. Nikolopoulos G., Pyrpassopoulos S., Thanassoulas A., Klimentzou P., Zikos C., Vlassi M., Vorgias C.E., Yannoukakos D., and Nounesis G. Thermal unfolding of human BRCA1 BRCT-domain variants. Biochim. Biophys. Acta 1774 (2007) 772-780
53. Grantham R. Amino acid difference formula to help explain protein evolution. Science 185 (1974) 862-864
54. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., and Ferrin T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004) 1605-1612
55. Shackleford G., and Karplus K. Contact prediction using mutual information and neural nets. Proteins 69 Suppl. 8 (2007) 159-164
56. Chenevix-Trench G., Healey S., Lakhani S., Waring P., Cummings M., Brinkworth R., et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 66 (2006) 2019-2027
57. Malacrida S., Agata S., Callegaro M., Casella C., Barana D., Scaini M.C., et al. BRCA1 p. Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. J. Clin. Oncol. 26 (2008) 26-31